Xbrane Biopharma AB is a Swedish pharmaceutical company specializing in biosimilars. With a focus on sustainability and governance, Xbrane develops cost-effective alternatives to already approved biological drugs. The company's patented protein production platform offers higher productivity compared to traditional systems, particularly in E.coli host cells. Xbrane's key product candidate, Ximluci, is a ranibizumab biosimilar used to treat eye diseases such as age-related macular degeneration. With an ESG score of 27.5, Xbrane is considered to have a medium risk profile in the industry.